Although various government incentives have been introduced in the past few years to encourage and support more research and development designed to accelerate the discovery of new antibiotics, they, in themselves, have not been enough.

The disturbing fact is that antimicrobial resistance (AMR) is outpacing the current drug arsenal available to keep it in check and, what’s even worse, the current reimbursement environment tends to work against the use of innovative drugs that are being approved for treating drug-resistant infections.

Read more at BioWorld Insight.